Results 231 to 240 of about 38,450 (306)

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2162-2170, July 2026.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas. [PDF]

J Hematol Oncol
Munir M, Sayed A, Lee DH, Awan F, Ghazi S, Kim J, Addison D, Epperla N.   +7 more
europepmc   +1 more source

Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B‐ALL After CAR‐T Therapy and HSCT: A Case Series

Cancer Reports, Volume 9, Issue 7, July 2026.
ABSTRACT Background Although inotuzumab ozogamicin (InO) has been approved as an effective agent for patients with refractory/relapsed (r/r) B‐cell acute lymphoblastic leukemia (B‐ALL), data in the context of post chimeric antigen receptor (CAR)‐T cell therapy and allogeneic hematopoietic stem cell transplantation (allo‐HSCT) relapse are lacking.
Honghu Li, Luxin Yang, Lizhen Liu, Xiaoyu Lai, Lixia Zhu, Kui Zhao, Qian Luo, He Huang, Yi Luo   +8 more
wiley   +1 more source

TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy. [PDF]

Signal Transduct Target Ther
Ding Z, Sun S, Yang X, Huang X, Hou X, Xie S, Liu A, Lu X.   +7 more
europepmc   +1 more source

Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report [PDF]

Rev Fac Cien Med Univ Nac Cordoba
Milanesio M, Olmedo J, Caeiro G, Basquiera AL.   +3 more
europepmc   +1 more source

Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis. [PDF]

PLoS Pathog
Akanksha, Bouzeyen R, Watson A, Wiseglass G, Sithole N, Abramovitz L, Ben-Shalom N, Rubinstein R, Javid B, Freund NT.   +9 more
europepmc   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, Volume 159, Issue 1, Page 11-29, 1 July 2026.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source

The Year of the Bispecific

The Hematologist
openaire   +1 more source

Non-factor Therapies in Hemophilia: Mechanisms, Clinical Evidence, Patient Management, and Future Perspectives. [PDF]

Adv Ther
Nakajima Y, Nogami K.
europepmc   +1 more source

Osimertinib Resistance in EGFR‐Mutated Non–Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies

MedComm, Volume 7, Issue 7, July 2026.
This review illustrates the key mechanisms of osimertinib resistance in EGFR‑mutant NSCLC, including EGFR‑dependent mutations, bypass pathway activation, and SMARCA4‑mediated epigenetic regulation. We also summarize emerging targeted therapies and future perspectives to overcome EGFR‑TKI resistance.
Junfeng Guo, Qiuyuan Wen, Songqing Fan
wiley   +1 more source